Soluble neprilysin retains catalytic activity in heart failure

Neprilysin (NEP) is a transmembrane receptor active in the degradation of a plethora of vasoactive peptides. Very recently, NEP has gained focus as a heart failure (HF) biotarget.1 Indeed, in the PARADIGM-HF trial, the novel drug sacubitril-valsartan elegantly demonstrated superior clinical efficacy of dual inhibition (NEP and AT1 receptor inhibition) over the standard-of-care treatment (enalapril).2 The soluble form of NEP has biomarker potential in heart failure. Our group demonstrated that the circulating soluble form of NEP (sNEP) is measurable in patients with chronic and acute HF.

Source: The Journal of Heart and Lung Transplantation - January 6, 2016 Category: Transplant Surgery Authors: Antoni Bayes-Genis, Timothy C. Prickett, A. Mark Richards, Jaume Barallat, Josep Lupón Tags: Research Correspondence Source Type: research